House E&C Subcommittee on Health Holds Another Hearing on Health Care Affordability
The House Committee on Energy and Commerce Subcommittee on Health held another hearing on June 10 in its affordability series to explore more...
1 min read
On May 29, Medicare announced it would expand coverage for genomic sequence analysis panels in the treatment of hematolymphoid diseases.
The local coverage determination (LCD) “provides limited coverage for genomic sequence analysis panels under specific clinical circumstances.” Specifically, these multi-gene panel tests would be used for diagnosis, risk stratification, and treatment planning for patients with hematolymphoid diseases, including newly diagnosed or relapsed/refractory acute myelogenous leukemia, myelodysplastic syndromes with nondiagnostic assessments, and myeloproliferative neoplasms requiring risk stratification or disease monitoring.
The College of American Pathologists applauded the proposed updates in a 2024 letter, expressing support for the decision to broaden coverage. According to CAP, the policy aligns with the National Comprehensive Cancer Network guidelines and the World Health Organization classifications.
The revision is effective for services performed on or after July 13, 2025.
Sources:
https://www.cap.org/advocacy/latest-news-and-practice-data/june-10-2025#story5
TELCOR POC Device Connectivity Updates -2026 Q1
Lincoln, NE - June 16, 2026 TELCOR QML® has connectivity for more than 160 device types. Whether you are looking to add new testing on devices...
TELCOR Brings New Operator Management Capabilities to ADLM 2026
Lincoln, NE – June 12, 2026 – TELCOR Inc, the industry leader in healthcare software for point of care testing and laboratory revenue cycle...